RAFAGEN is established to commercialize its patented synthetic gene promoter technology in biologics drug development and manufacturing.
RAFAGEN's core technology has applications in two different but critical areas of biopharmaceuticals. In drug development, the technology can be applied to minimize harmful drug effects. In biologics manufacturing procedure, it can minimize the cost by maximizing production efficiency. RAFAGEN strives first to establish a strong revenue stream in biologics manufacturing field, and then to peruse its long term goal of cancer drug development.